{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:59:51Z","timestamp":1776722391527,"version":"3.51.2"},"reference-count":16,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Medical Case Reports"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Venetoclax, a BCL-2 inhibitor used in chronic lymphocytic leukemia and acute myeloid leukemia, has been rarely associated with autoimmune hemolytic anemia, mostly in chronic lymphocytic leukemia. We report the first case of venetoclax-triggered autoimmune hemolytic anemia in acute myeloid leukemia secondary to chronic myelomonocytic leukemia. An 80-year-old man developed abrupt warm autoimmune hemolytic anemia 4\u2009days after venetoclax initiation with azacitidine. Hemolysis resolved rapidly after venetoclax withdrawal and corticosteroid therapy. Rechallenge led to compensated hemolysis. This case supports venetoclax causality and highlights that autoimmune hemolytic anemia can occur beyond lymphoid malignancies. Clinicians should monitor for autoimmune cytopenias during venetoclax therapy, even in myeloid disorders.<\/jats:p>","DOI":"10.1177\/2050313x261436897","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T01:30:57Z","timestamp":1774834257000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Venetoclax as a trigger for autoimmune hemolytic anemia in secondary acute myeloid leukemia: A case report"],"prefix":"10.1177","volume":"14","author":[{"given":"Karima","family":"Benallaoua","sequence":"first","affiliation":[{"name":"H\u00e9matologie Clinique, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Lacoeuilhe","sequence":"additional","affiliation":[{"name":"Pharmacie Hospitali\u00e8re, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"Gendrot","sequence":"additional","affiliation":[{"name":"INSERM U1016, Institut Cochin, CNRS UMR8104, Facult\u00e9 de M\u00e9decine Cochin-Port Royal, Universit\u00e9 de Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahra","family":"Muhammad","sequence":"additional","affiliation":[{"name":"Pharmacie Hospitali\u00e8re, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-393X","authenticated-orcid":false,"given":"Guillemette","family":"Fouquet","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Clinique, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France"},{"name":"Universit\u00e9 Paris Saclay, Gustave Roussy, INSERM U1287, Cellules Souches H\u00e9matopo\u00ef\u00e9tiques et D\u00e9veloppement d\u2019H\u00e9mopathies Malignes, Villejuif, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/20406207251343116"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1243681"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.928514"},{"issue":"5","key":"e_1_3_3_5_2","first-page":"166","article-title":"Autoimmune hemolytic anemia, adverse event to venetoclax","volume":"43","author":"Carriles C","year":"2019","unstructured":"Carriles C, Ord\u00f3\u00f1ez-Fern\u00e1ndez L, Arias-Mart\u00ednez A, et al. Autoimmune hemolytic anemia, adverse event to venetoclax. Farm Hosp 2019; 43(5): 166\u2013167.","journal-title":"Farm Hosp"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.2174\/0113892002338926241114080504"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1941932"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3761"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008201"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00070-6"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_3_3_13_2","volume-title":"Initial clinical guidance report: venetoclax (Venclexta) rituximab for chronic lymphocytic leukemia","author":"CADTH Pan-Canadian Oncology Drug Review","year":"2019","unstructured":"CADTH Pan-Canadian Oncology Drug Review. Initial clinical guidance report: venetoclax (Venclexta) rituximab for chronic lymphocytic leukemia (pERC meeting: March 21, 2019). CADTH, 2019."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2010.27"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00073"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2011.12.008"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1338"}],"container-title":["Sage Open Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X261436897","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050313X261436897","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050313X261436897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:16:13Z","timestamp":1774991773000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050313X261436897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":16,"alternative-id":["10.1177\/2050313X261436897"],"URL":"https:\/\/doi.org\/10.1177\/2050313x261436897","relation":{},"ISSN":["2050-313X","2050-313X"],"issn-type":[{"value":"2050-313X","type":"print"},{"value":"2050-313X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"2050313X261436897"}}